ARCHIVE

Hisamitsu to Launch Norspan Tape in Early August Aiming for ¥1.3 Bil. Sales in FY2011

July 18, 2011
Hisamitsu Pharmaceutical aims to launch its long-lasting transdermal pain-relieving agent Norspan Tape (buprenorphine) in early August following its NHI price listing expected during July. Hisamitsu intends to promote the drug through all of its 600 MRs targeting orthopedic surgeons and…

To read the full story

ARCHIVE

By Ken Yoshino

As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…

By Ken Yoshino

Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…